Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Total Non-Current Liabilities (2023 - 2024)

Artiva Biotherapeutics (ARTV) has disclosed Total Non-Current Liabilities for 2 consecutive years, with $22.9 million as the latest value for Q4 2024.

  • On a quarterly basis, Total Non-Current Liabilities fell 54.85% to $22.9 million in Q4 2024 year-over-year; TTM through Dec 2024 was $22.9 million, a 54.85% decrease, with the full-year FY2024 number at $22.9 million, down 54.85% from a year prior.
  • Total Non-Current Liabilities was $22.9 million for Q4 2024 at Artiva Biotherapeutics, down from $24.5 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $50.6 million in Q4 2023 to a low of $22.9 million in Q4 2024.